LONDON: Roquefort Therapeutics (LSE:ROQ), a biotech company focused on developing innovative immunology and oncology medicines, has announced a term sheet agreement for the sale of its subsidiary, Oncogeni Ltd, to The Nations Trust Holding LLC. The deal is valued at up to $12 million in cash, including upfront and milestone payments. Roquefort Therapeutics and Nations…
All posts tagged sale of subsidiary
Roquefort Therapeutics signs term sheet for $10 million sale of subsidiary
LONDON: Roquefort Therapeutics (LSE:ROQ), a publicly traded biotech company, announced it has signed a term sheet for the sale of its wholly-owned subsidiary, Lyramid Pty Ltd, to Pleiades Pharma Limited. The proposed deal values Lyramid at a minimum of $10 million. Roquefort and Pleiades plan to finalize the transaction within 30 days. The agreement includes…